Vicinitas Therapeutics

Utilizing DUBTAC technology to develop next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins.

[Vicinitas Therapeutics @VicinitasTx]

We're pleased to appoint Christian Hofmann, Ph.D. as our CEO and member of the board of directors. Dr. Hofmann brings more than two decades of biopharma experience, and we're thrilled to welcome him to Vicinitas. https://t.co/ZyGMGUzVMW

[Vicinitas Therapeutics @VicinitasTx]

Introducing Vicinitas Therapeutics, a new venture focused on advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in #cancer and genetic disorders. Learn more about Vicinitas' mission from founder @DanNomura. https://t.co/EIQDYx3IFS